Michael Joseph Rybak Pharm.D., M.P.H., Ph.D.

Michael Joseph Rybak Pharm.D., M.P.H., Ph.D.

Title

Professor

Department

Pharmacy Practice

Office Location

EACPHS, Room 4148

Phone

313-577-4376

Email

m.rybak@wayne.edu

Michael Joseph Rybak Pharm.D., M.P.H., Ph.D.

Degrees and Certifications

Degrees

  • 2011-2016 - Ph.D., Public Health, Walden University
  • 1998-2005 - M.P.H., Wayne State University School of Medicine
  • 1979-1981 - Pharm.D., Wayne State University, Pharmacy
  • 1976-1979 - B.S., Northeastern University, Boston, Pharmacy
  • 1975-1976 - State University College of Buffalo, Buffalo, Biology
  • 1973-1975 - Associates Erie Community College, Amherst, Science

Certification

  • 2000 - Board Certified Pharmacotherapy Specialist 9/82. Added Qualifications for Infectious Diseases Pharmacotherapy 

Positions and Employment

  • 1993-Present - Professor of Pharmacy and Adjunct Professor of Medicine, Wayne State University
  • 2008-2011 - Associate Dean for Research, EACPHS, Wayne State University
  • 1987-1993 - Associate Professor, EACPHS, Wayne State University
  • 1981-1987 - Assistant Professor of Pharmacy Practice 

Awards and Honors

  • 2018 - Charles H. Gershenson Distinguished Faculty Fellows award
  • 2018 - Van Greene Lecture Award, 2018
  • 2016 - American College of Clinical Pharmacy Therapeutics Frontiers Lecture Award
  • 2013 - Preceptor for the Outstanding Student Poster Award in Clinical Sciences
  • 2011 - Outstanding Achievement in Clinical Sciences Research Award
  • 2011 - Lead Industry Collaborator Award, Wayne State University
  • 2007 - ACCP-Ortho-McNeil Infectious Diseases Fellowship Award
  • 2005 - Distinguished Alumni Award, Wayne State University
  • 2004 - The Russell R. Miller Award for Recognition of Sustained and Outstanding Contributions to the Literature of Clinical Pharmacy
  • 2003 - The Ted Goldberg Prize in Community Health
  • 2003 - ACCP-Merck Infectious Diseases Fellowship Award
  • 2002 - American Society of Health-System Pharmacists, Award for Sustained Literature Contributions to the Pharmacy Literature for ASHP
  • 2000 - Impact paper in ID Pharmacists Research Award, SIDP
  • 1997 - Distinguished Faculty Fellowship Award, Wayne State University
  • 1996 - Fellow, Infectious Disease Society of America
  • 1992 - Wayne State University Career Chair Development Award
  • 1992 - R.W. Johnson Research Institute Fellowship Award
  • 1991 - Wayne State University Academic Achievement Award for Natural Sciences
  • 1991 - American College of Clinical Pharmacy Fellow Recognition Award
  • 1990 - Merck Foundation Fellowship Award
  • 1990 - The Upjohn Pharmacy Research Award, Michigan Society of Hospital Pharmacists

Professional Memberships

  • 2016-Present - Honors and Awards Committee Roster and Charges
  • 2008-Present - European Society of Clinical Microbiology and Infectious Diseases
  • 2005-Present - Society of Healthcare Epidemiology of America
  • 2003-Present - ASHP Research Foundation
  • 2000-Present - Michigan Antibiotic Resistance Committee
  • 1998-Present - Alliance for the Prudent Use of Antibiotics
  • 1991-Present - Infectious Diseases Society of America
  • 1990-Present - Society of Infectious Diseases Pharmacists
  • 1990-Present - Michigan Society of Hospital Pharmacists
  • 1990-1993 - FDA - Regional Task Force on AIDS Fraud
  • 1989-Present - American Society of Microbiology
  • 1985-1987 - Board Liaison to Membership Committee
  • 1985-1987 - Southeastern Society of Hospital Pharmacists Board of Directors
  • 1984-1985 - Program and Seminar Committee
  • 1983-1987 - Michigan Board of Pharmacy - Internship Committee
  • 1983-Present - Phi Delta Chi Pharmaceutical Fraternity
  • 1982-Present - American College of Clinical Pharmacy
  • 1982-Present - American Association of Colleges of Pharmacy
  • 1982-1987 - American Society of Hospital Pharmacists
  • 1981-Present - Rho Chi Pharmaceutical Honor Society
  • 1981-Present - American Society of Health-System Pharmacists
  • 1981-Present - Southeastern MI Society of Hospital Pharmacists
  • 1976-1979 - Massachusetts Society of Hospital Pharmacists

Primary Research Interest

  • Dr. Rybak’s primary focus of research is antimicrobial pharmacokinetics and pharmacodynamics (PK/PD) and the assessment of infectious diseases health outcomes, including their relationship to bacterial resistance. His most recent work is focused on the laboratory and clinical outcomes assessment of combination therapy for methicillin and vancomycin-resistant Staphylococcus aureus, enterococcus and gram-negative pathogens.

Recent Publications

Last Two Years

  • Corey G, McKinnell J, Rybak MJ. Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019 Apr 8;68(Supplement_3): S191-S192. doi: 10.1093/cid/ciy1089. PubMed PMID: 30957163.
  • Kebriaei R, Rice S, Stamper K, Rybak MJ. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated
  • Xiaoju L, Alder J, Li L, O'Riordan W, Rybak MJ, Ye H, Zhang R, Zhang Z, Zhu X, Wilcox M. "Efficacy and safety of tedizolid phosphate versus linezolid in a randomized Phase 3 trial in patients with acute bacterial skin and skin structure infection". Accepted to Antimicrob Agents Chemother (April 2019).
  • Kebriaei R, Rice S, Stamper K, Rybak MJ. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model. Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01743-18
  • Claey K, Zasowski E, Trihn T, Casapao A, Pogue J, Bhatia N, Mynatt R, Wilson S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine D, Kaye K, Delgado G, Giuliano C, Takla R, Rieck C, Johnson L, Murray K, Gordon J, Reyes K, Hartman P, Davis S, Rybak MJ. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus. Infect Dis Ther (2019). https://doi.org/10.1007/s40121-019-0242-5
  • Abdul-Mutakabbir J, Kebriaei R, Jorgensen S. Rybak MJ. Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomici. Infect Dis Ther. 2019 March 09. https://doi.org/10.1007/s40121-019-0239-0
  • V I Rolston K, Jamal M, Nesher L, Raad I, Rice S, Rybak MJ, Prince RA. Bactericidal activity of ceftaroline, vancomycin, daptomycin against methicillin-resistant staphylococcus aureus isolates from cancer patients. J Glob Antimicrob Resist. 2019 Mar 4. https://doi.org/10.1016/j.jgar.2019.02.018
  • Zasowski E, Trinh T, Atwan S, Merzlyakova M, Langf A, Bhatia S, Rybak MJ. The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections treated with Vancomycin. Open Forum Infect Dis. 2019 Feb 27. https://doi.org/10.1093/ofid/ofz077
  • Jorgensen S, Lagnf A, Bhatia S, Singh N, Shammout L, Davis S, Rybak MJ. Diagnostic stewardship: a clinical decision rule for blood cultures in community-onset methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Infect Dis Ther. 2019 February 19. doi: 10.1007/s40121-019-0238-1.
  • Jorgensen S, Lagnf A, Bhatia S, Rybak MJ. A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2019 Feb 8. doi: 10.1007/s10096-018-03464-0.
  • Jorgensen S, Lagnf A, Bhatia S, Singh N, Shammout L, Davis S, Rybak MJ. Diagnostic stewardship: a clinical decision rule for blood cultures in community-onset methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Infect Dis Ther. 2019 February 19. doi: 10.1007/s40121-019-0238-1.
  • Zasowski E, Trinh T, Atwan S, Merzlyakova M, Langf A, Bhatia S, Rybak MJ. The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections treated with Vancomycin. Open Forum Infect Dis. 2019 Feb 27. https://doi.org/10.1093/ofid/ofz077
  • Jorgensen S, Lagnf A, Bhatia S, Singh N, Shammout L, Davis S, Rybak MJ. Diagnostic stewardship: a clinical decision rule for blood cultures in community-onset methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Infect Dis Ther. 2019 February 19. doi: 10.1007/s40121-019-0238-1.
  • Jorgensen S, Lagnf A, Bhatia S, Rybak MJ. A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2019 Feb 8. doi: 10.1007/s10096-018-03464-0.
  • Alosaimy S, Jorgensen S, Rybak MJ. The Optimal Use of the Polymyxins Before their Time is Up. Pharmacother. January 08, 2019. (DOI) - 10.1002/phar.2207
  • Tran T, Mishra N, Seepersaud R, Diaz L, Rios R, Dinh AQ, Garcia-de-la-Maria C, Rybak MJ, Miro JM, Shelburne S, Sullam PM, Bayer AS, Arias CA. Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in S. mitis /oralis. Antimicrob Agents Chemother. 2018 Dec 3. https://doi.org/10.1128/AAC.01531-18
  • Rybak MJ, Zasowski E, Jorgensen S, Lagnf A, Davis S, Mendelsohn A, Margaritis V. Risk Factors for Bloodstream Infections among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. Infect Dis Ther. 2018 December 04. https://doi.org/10.6084/m9.figshare.7416182
  • Jorgensen S, Lagnf A, Bhatia S, Muhammad-Daniayl S, Rybak MJ. Sequential Intravenous-to-Oral Outpatient Antibiotic Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: One Step Closer. J Antimicrob Chemother. 2018 Nov 09 https://doi.org/10.1093/jac/dky452
  • Heil E, Claeys K, Mynatt R, Hopkins T, Brade K, Watt I, Rybak MJ, Pogue J. Making the change to area under the curve–based vancomycin dosing. Am J Health-System Pharm October 2018, ajhp180034; DOI: https://doi.org/10.2146/ajhp180034
  • Xhemali X, Smith J, Kebriaei R, Rice S, Stamper K, Compton M, Singh N, Jahanbakhsh S, Rybak MJ. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. J Antimicrob Chemother. 2018 Sep 27. https://doi.org/10.1093/jac/dky376
  • Claeys K, Zasowski E, Lagnf A, Sabagha N, Levine D, Davis S, Rybak MJ. Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute HealthcareSetting. Infect Dis Ther. 2018 Sep 22. https://doi.org/10.1007/s40121-018-0212-3
  • Avery L, Kuti J, Weisser M, Egli A, Rybak MJ, Zasowski E, Arias C, Contreras G, Chong P, Aitken S, DiPippo A, Wang J, Britt N, Nicolau D. Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clin Infect Dis. 2018 September 5. https://doi.org/10.1093/cid/ciy749
  • Jorgensen S, Mcdonald P, Mynatt R, Pogue J, Lerner S, Dhar S, Salimnia H, Rybak MJ. Averting the post-antibiotic era: successful use of meropenem-vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteremia in a hemodialysis patient. J Antimicrob Chemother. 2018 September 4. https://doi.org/10.1093/jac/dky346
  • Tran T, Mishra N, Diaz L, Rios R, Dinh A, Seepersaud R, Garcia de la Maria C, Rybak MJ, Miro J, Sullam P, Shelburne S, Bayer A, Arias C. Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in S. mitis/oralis. Antimicrob Agents Chemother. 2018 January. 63(2); https://doi.org/10.1128/AAC.01531-18.
  • Bhise K, Sau S, Kebriaei R, Rice S, Stamper K, Alsaab H, Rybak MJ, Iyer A. Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA. Materials (Basel). 2018 July 20. 11(7), 1245; https://doi.org/10.3390/ma11071245
  • Jahanbakhsh S, Singh N, Yim J, Rybak MJ. Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus (MRSA) in an in vitro Biofilm Model. Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00567-18. doi: 10.1128/AAC.00567-18. [Epub ahead of print]
  • Kebriaei R, Rice S, Singh K, Stamper K, Dinh A, Rios R, Dias L, Murray B, Munita J, Tran T, Arias C, Rybak MJ. Efficacy of Daptomycin Monotherapy and In Combination with Beta-Lactams for Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions Influence of The Inoculum Effect. Antimicrob Agents Chemother. 2018 May 14. pii: AAC.00315-18. doi: 10.1128/AAC.00315-18. [Epub ahead of print]
  • Singh N, Yim J, Jahanbakhsh S, Sakoulas G, Rybak MJ. Impact of Cefazolin Co-administration with Vancomycin to Reduce Development of Vancomycin Intermediate Staphylococcus aureus. Diagn Microbiol Infect Dis. 2018 April 7. pii: S0732-8893(18)30113-5. doi: 10.1016/j.diagmicrobio.2018.03.020. [Epub ahead of print] PMID: 29807674
  • Jorgensen S, Mercuro N, Davis S, Rybak MJ. Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. Infect Dis Ther. 2018 March 31. https://doi.org/10.1007/s40121-018-0198-x
  • Tran K, Rybak MJ. Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA. Antimicrobial Agents and Chemotherapy. 2018 March 19. doi: 10.1128/AAC.00157-18.
  • Smith JR, Yim J, Rice S, Kebriaei R, Rybak MJ. The combination of tedizolid and daptomycin against methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrobial Agents and Chemotherapy. 2018 March 12. doi: 10.1128/AAC.00101-18.
  • Jorgensen , Rybak MJ. Meropenem and vaborbactam: Stepping up the battle against carbapenem-resistant Enterobacteriaceae. Pharmacotherapy. 2018 Feb 10. doi: 10.1002/phar.2092
  • Trinh TD, Zasowski EJ, Claeys KC, Casapao AM, Compton M, Lagnf AM, Kidambi SD, Levine DP, Rybak MJ. Role of Vancomycin Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections. Infectious Diseases and Therapy. 2018 February 22. doi: 10.1007/s40121-018-0187-0.
  • Beganovic M, Luther M, Rice L, Arias C, Rybak MJ, LaPlante KL. A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis. 2018 Jan 30. doi: 10.1002/phar.2092

Research website

https://www.ncbi.nlm.nih.gov/pubmed/?term=rybak+mj

Laboratory Web Site

http://cphs.wayne.edu/research/anti-infective-lab.php